Critical Comparison: Surrozen (NASDAQ:SRZN) & AIM ImmunoTech (NYSE:AIM)

Surrozen (NASDAQ:SRZN) and AIM ImmunoTech (NYSE:AIM) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Analyst Recommendations

This is a summary of recent ratings and price targets for Surrozen and AIM ImmunoTech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	0	0	0	0	N/A
AIM ImmunoTech	0	0	0	0	N/A

Risk & Volatility

Surrozen has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, AIM ImmunoTech has a beta of -0.35, meaning that its share price is 135% less volatile than the S&P 500.

Earnings & Valuation

This table compares Surrozen and AIM ImmunoTech’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$12.50 million	1.83	-$43.04 million	N/A	N/A
AIM ImmunoTech	$193,000.00	70.57	-$28.96 million	($0.64)	-0.41

AIM ImmunoTech has lower revenue, but higher earnings than Surrozen.

Insider & Institutional Ownership

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 12.0% of AIM ImmunoTech shares are owned by institutional investors. 43.5% of Surrozen shares are owned by company insiders. Comparatively, 0.0% of AIM ImmunoTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Surrozen and AIM ImmunoTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Surrozen	N/A	-85.54%	-71.86%
AIM ImmunoTech	-16,123.32%	-191.38%	-128.26%

Summary

Surrozen beats AIM ImmunoTech on 7 of the 9 factors compared between the two stocks.

About Surrozen

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

About AIM ImmunoTech

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.